Figure 6 | Scientific Reports

Figure 6

From: LTP-1, a novel antimitotic agent and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo

Figure 6

LTP-1 suppressed AsPC-1 human pancreatic adenocarcinoma growth in vivo.

AsPC-1 xenograft nude mice were intraperitoneally (i.p.) administered LTP-1 (50, 100 or 200 mg/kg), Gemcitabine (100 mg/kg), or vehicle after tumor cell implantation. (A) LTP-1-inhibited tumor growth in mice. (B) body weight of tumor bearing mice under the treatment during the study. Data represent mean ± SEM from eight mice in each group. (P < 0.05 and P < 0.001 versus control group).

Back to article page